Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer

In this issue, we have reviewed the current status of imaging and blood-based biomarkers in translational lung cancer research. Clearly, some small but important initial steps have been made toward realizing precision medicine approaches for this disease, and research in this area has revealed significant opportunities to address unmet needs and validate imaging and blood-based biomarkers in clinical trials.